Pentadecapeptide BPC 157 attenuates thrombosis, vein injury, and hemodynamic collapse after major vein ligation in rats.

Ligation of the inferior caval vein (ICV), a major blood vessel, is a model that recapitulates Virchow's triad: endothelial injury, venous stasis, and a hypercoagulable state, leading to severe thrombosis. This procedure induces a dangerous syndrome including widespread clot formation, tissue damage from oxidative stress (measured by MDA levels), and significant hemodynamic collapse, characterized by venous hypertension upstream of the blockage and arterial hypotension system-wide. The body's natural response, forming collateral vessels to bypass the obstruction, is often too slow or insufficient to prevent damage. This research investigates the stable gastric pentadecapeptide BPC 157 as a potential therapeutic agent to rapidly counteract this entire pathological cascade, from the initial vessel injury and thrombosis to the systemic circulatory failure and molecular-level damage.

This was an animal study conducted in rats. Researchers surgically ligated the inferior caval vein (ICV) up to the right ovarian vein to induce thrombosis and circulatory disruption. The intervention group received the stable gastric pentadecapeptide BPC 157 at doses of 10 μg/kg or 10 ng/kg. The peptide was administered either as an early or delayed therapy regimen. The study assessed a wide range of outcomes, including gross observation via microcamera, microscopy, venography to visualize blood flow, bleeding time, blood pressure, ECG, thermography, and biochemical markers like malondialdehyde (MDA) and nitric oxide (NO) levels in both plasma and ICV tissue. Gene expression analysis for EGR, NOS, SRF, VEGFR, and KRAS was also performed.

BPC 157 therapy effectively counteracted the full syndrome induced by ICV ligation. It mitigated direct vein injury, reduced thrombosis, and corrected thrombocytopenia and prolonged bleeding times. Treated rats showed a rapid presentation of functional collateral vessels, which successfully bypassed the ligature through pathways like the left ovarian vein. This vascular rescue redistributed the trapped blood volume, counteracting the otherwise severe venous hypertension and arterial hypotension. On a biochemical level, rats treated with BPC 157 exhibited raised plasma NO levels while maintaining normal plasma MDA levels, indicating reduced systemic oxidative stress. In the local ICV tissue itself, BPC 157 reversed the dangerously low NO levels and counteracted the increased MDA levels, suggesting localized vasoprotective and antioxidant effects. Gene expression was also significantly altered in the ICV, ROV, and LOV tissues of treated animals.

Written by TitrateLab, separately from the study summarized above.